New data released by the U.S. Food and Drug Administration (FDA) reveals that since the year 2012, more than 40,000 people have suffered adverse reactions from taking the hormone-blocking pharmaceutical Lupron (leuprolide acetate), while at least 6,370 people have died since 2014 from taking the drug.
Commonly prescribed to children who’ve been manipulated into believing that they’re “transgenders” in need of a chemical “sex change,” Lupron has reportedly caused more than 25,500 “serious” reactions in patients just in the last five years, according to the FDA. Many of these adverse reactions appear to have occurred in patients who were prescribed the drug for off-label uses, such as in transgender “therapy.”
While Lupron is clinically approved for use in treating “precocious puberty,” or abnormally early puberty that could cause other health problems, it is not approved for use in children with gender dysphoria. But this is how Lupron is now being widely prescribed, putting the health of children with gender dysphoria at serious risk.
The pediatric version of the drug is also largely mislabeled, as it comes with minimal warnings about long-term side effects, some of which could be irreversible. Such irreversible side effects include permanent damage to the endocrine system, which is responsible for producing the sex hormones that sustain life.
“It’s a serious condition that endocrinologists would normally diagnose and treat because it interferes with development, but in [gender dysphoria] cases they’re inducing this disease state,” says Michael Laidlaw, a Rocklin, California-based endocrinologist, as quoted by the National Catholic Register.
If the FDA really launched a review of Lupron’s safety back in 2017, why has nothing been done two years later?
The FDA has known for at least two years that Lupron isn’t necessarily safe, especially for young children. The agency announced back in 2017 that it was “conducting a specific review of nervous system and psychiatric events in association with the use of GnRH agonists, [a class of drugs] including Lupron, in pediatric patients.”
However, nothing thus far has come out of this alleged inquiry, which first came about as a result of questions that were raised by Kaiser Health News and Reveal from the Center for Investigative Reporting, including why so many children who are being given Lupron now suffer from persistent seizures.
While transgender activists claim that Lupron and similar such drugs function merely as a “pause button” on life, and are thus completely safe, the data suggests otherwise. By inhibiting the flow of testosterone over the prostate, reducing it to low or undetectable levels, Lupron is a dangerous endocrine disruptor, especially in children.
Since Lupron was designed with prostate cancer in mind, this is what it should be prescribed for in exclusivity – and not for treating psychological conditions like gender dysphoria by depriving children of the hormones they need to live.
“Gender dysphoria is not an endocrine condition, but is a psychological one and should, therefore, be treated with proper psychological care,” Laidlaw is further quoted as saying. “But it becomes an endocrine condition once you start using puberty blockers and giving cross-sex hormones to kids.”
In the United States alone in 2017, prescriptions for Lupron, which is manufactured by drug giant AbbVie, rake in about $669 million for the company annually. And with gender dysphoria on the rise due to rampant transgender indoctrination, that number is likely to skyrocket even more.